NBIX Neurocrine Biosciences, Inc.
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances) · Market cap $14.9B · $143.18 on 2026-10-02
Above StickerTier CDetailed (TTM)
Price moves
1 week3%
1 month-8%
3 months-18%
6 months9%
YTD5%
1 year4%
Off 52w high-23%
52w range$122–$186
Price history
Show year-end values
| Year | Price |
|---|---|
| 2016 | $38.70 |
| 2017 | $77.59 |
| 2018 | $71.41 |
| 2019 | $107.49 |
| 2020 | $95.85 |
| 2021 | $85.17 |
| 2022 | $119.44 |
| 2023 | $131.76 |
| 2024 | $136.50 |
| 2025 | $141.83 |
| 2026-10-02 (latest) | $143.18 |
Buy (MOS)
$5
$5
Sticker
$10
$10
Payback Time
$75
$75
Ten Cap
$84
$84
Price
$143
$143
Analyst consensus 29 analysts · as of 2026-10-09 · the street vs Rule #1
Crowded Targets $164 low · $207 mean · $253 high (+45% to the mean)
Analysts love it but the price is above Sticker. Good news is already priced in.
Low
$164
$164
Mean
$207
$207
High
$253
$253
Buy (MOS)
$5
$5
Sticker
$10
$10
Price
$143
$143
Average rating 1.4 of 5 (1 = strong buy, 5 = sell) · strong buy · EPS growth next year 16% vs windage 2.3%
A price target is a 12-month price opinion, not a valuation. Rule #1 treats analysts as a lead and their growth as a ceiling (077, 093). Source: Yahoo Finance consensus.
Valuation
| Buy (MOS) 50% of Sticker | $4.99 | -97% |
|---|---|---|
| Ten Cap 10× owner earnings − net debt | $83.85 | -41% |
| Payback Time 8-year FCF payback | $74.55 | -48% |
| Sticker Rule #1 intrinsic value | $9.97 | -93% |
| Methods agree price under how many of Ten Cap, Payback, MOS | 0 of 3 | |
| Windage growth g | 2.3% | |
| Future P/E (min 2g, 10y median) | 4.7× | |
| P/E · 10y median | 20.9× | 51.4× |
| EPS TTM 2026-06-30 | $6.84 | |
| FCF yield | 5.9% | |
| Dividend (TTM) · yield | – | – |
| Total return per year, dividends reinvested · 5y · 10y | 8.2% | 12.0% |
| Revenue · net income last FY | $2.9B | $479M |
Big Five 11/15 tests ≥10%
| 10y | 5y | 1y | |
|---|---|---|---|
| ROIC | 2% | 11% | 13% |
| Sales growth | 64% | 22% | 21% |
| EPS growth | – | 2% | 42% |
| BVPS growth | 20% | 22% | 27% |
| OCF growth | – | 28% | 31% |
| Debt payoff (yrs of FCF) | 0.0 |
Events
-23% off 52w high; 8-K: 2026-09-28: 5.02 Director/officer change; next report ~2026-10-30
Next report ≈ 2026-10-30 · SEC filings ·Yahoo Finance